Austrian Breast and Colorectal Cancer Study Group (ABCSG)

摘要

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Austrian Breast and Colorectal Cancer Study Group ABCSG. Clinical trials include:Adjuvant therapy with CMF versus goserelin plus tamoxifen in pre-menopausal, hormone-responsive, lymph node-positive or -negative patients. Study 5Adjuvant endocrine therapy in postmenopausal patients with hormone-responsive breast cancer: tamoxifen versus tamoxifen plus aminoglutethimide. Study 6Pre and postoperative chemotherapy versus conventional adjuvant chemotherapy alone in patients presenting with hormone receptor-negative breast cancer. Study 7Adjuvant endocrine therapy in postmenopausal patients with hormone-responsive breast cancer, G1 and G2 (ARNO). Study 8Adjuvant chemotherapy in postmenopausal patients with hormone-responsive breast cancer, G3. Study 9Adjuvant endocrine therapy and bisphosphonate therapy: tamoxifen in comparison to anastrozole, alone or in combination with zoledronate, in premenopausal patients presenting with hormone-responsive, Stage I and II breast cancer. Study 12Effect of 3 versus 6 cycles of epidoxorubicin/docetaxel G-CSF upon the rate of complete pathological remissions in the neoadjuvant treatment of patients with primary breast cancer and no distant metastases. Study 14SALSA (Secondary Adjuvant Long-term Study with Arimidex): a prospective, randomized, open, multicentre Phase III study to assess the efficacy of secondary adjuvant endocrine anastrozole therapy for 2 further years versus 5 further years in patients with hormone receptor-positive breast cancer after a 5-year primary adjuvant endocrine therapy. Study 16Neoadjuvant hormonal therapy with exemestane in postmenopausal patients with primary hormone receptor-positive breast cancer and no distant metastases. Study 17A randomized, double-blind, placebo-controlled, multi-centre phase 3 study to determine the treatment effect of denosumab in subjects with non-metastatic breast cancer receiving aromatase inhibitor therapy. Study 18A randomised Phase II study comparing anastrozole and fulvestrant to anastrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow. Study 21A randomized Phase III study comparing epirubicin, docetaxel and capecitabine G-CSF to epirubicin and docetaxel G-CSF as neoadjuvant treatment for early HER-2 negative breast cancer and comparing epirubicin, docetaxel and capecitabine G-CSF trastuzumab to epirubicin and docetaxel G-CSF trastuzumab as neoadjuvant treatment for early HER-2 positive breast cancer. Study 24